Literature DB >> 17453286

Genotype-phenotype based surgical concept of hereditary medullary thyroid carcinoma.

Andreas Machens1, Henning Dralle.   

Abstract

BACKGROUND: Since DNA tests have enabled reliable identification of asymptomatic RET (rearranged during transfection) gene carriers, myriads of publications have appeared on genotype-phenotype relationships. A comprehensive appraisal of this body of evidence using evidence-based methodology is pending.
METHODS: This study was based on systematic evaluation of the literature using evidence-based criteria.
RESULTS: (1) There is a distinct age-related progression of hereditary medullary thyroid carcinoma (MTC) in carriers of RET mutations (grade C). (2) Among the high-risk RET mutations, those in codon 634 cause higher penetrance rates of the multiple endocrine neoplasia 2A phenotype (MTC, pheochromocytoma, and parathyroid hyperplasia/adenoma) than mutations in codons 609, 611, 618, and 620, irrespective of the amino acid substituting for cysteine (grade C). (3) DNA-based screening is superior to calcitonin-based screening in asymptomatic RET carriers (grade C). (4) Using a worst-case scenario, i.e., considering the earliest finding of MTC in asymptomatic RET carriers, pre-emptive thyroidectomy should be performed before that time (grade C) to be truly prophylactic. Specifically, for carriers of highest-risk mutations (codon 918): within the first year of life; for carriers of high-risk mutations (codon 609, 611, 618, 620, 630, and 634): before the age of 5 years; and for carriers of least-high risk mutations (codon 768, 790, 791, 804, and 891): before the age of 5-10 years. Strict adherence to these grade C recommendations can result in undertreatment of the former (codon 634) and overtreatment of the latter.
CONCLUSIONS: These genotype-phenotype correlations provide a solid foundation on which to base surgical concepts, leaving little room for randomized controlled clinical trials.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17453286     DOI: 10.1007/s00268-006-0769-y

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  60 in total

Review 1.  DNA-based window of opportunity for curative pre-emptive therapy of hereditary medullary thyroid cancer.

Authors:  Andreas Machens; Henning Dralle
Journal:  Surgery       Date:  2006-03       Impact factor: 3.982

2.  Very early prophylactic thyroid surgery for infants with a mutation of the RET proto-oncogene at codon 634: evaluation of the implementation of international guidelines for MEN type 2 in a single centre.

Authors:  Christian Piolat; Jean-François Dyon; Nathalie Sturm; Stéphane Pinson; Michel Bost; Pierre-Simon Jouk; Dominique Plantaz; Olivier Chabre
Journal:  Clin Endocrinol (Oxf)       Date:  2006-07       Impact factor: 3.478

Review 3.  Seminars in medicine of the Beth Israel Hospital, Boston. The RET proto-oncogene in multiple endocrine neoplasia type 2 and Hirschsprung's disease.

Authors:  C Eng
Journal:  N Engl J Med       Date:  1996-09-26       Impact factor: 91.245

4.  Detection of medullary thyroid cancer by calcitonin assay in families.

Authors:  C E Jackson; A H Tashjian; M A Block
Journal:  Ann Intern Med       Date:  1973-06       Impact factor: 25.391

Review 5.  Guidelines for diagnosis and therapy of MEN type 1 and type 2.

Authors:  M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

6.  Molecular genetic diagnostic program of multiple endocrine neoplasia type 2A and familial medullary thyroid carcinoma syndromes in Hungary.

Authors:  I Klein; O Esik; V Homolya; F Szeri; A Váradi
Journal:  J Endocrinol       Date:  2001-09       Impact factor: 4.286

7.  Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A.

Authors:  Michael A Skinner; Jeffrey A Moley; William G Dilley; Kouros Owzar; Mary K Debenedetti; Samuel A Wells
Journal:  N Engl J Med       Date:  2005-09-15       Impact factor: 91.245

8.  Emergence of medullary thyroid carcinoma in a family with the Cys630Arg RET germline mutation.

Authors:  Andreas Machens; Ulrich Schneyer; Hans-Jürgen Holzhausen; Friedhelm Raue; Henning Dralle
Journal:  Surgery       Date:  2004-11       Impact factor: 3.982

9.  Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A.

Authors:  L M Mulligan; J B Kwok; C S Healey; M J Elsdon; C Eng; E Gardner; D R Love; S E Mole; J K Moore; L Papi
Journal:  Nature       Date:  1993-06-03       Impact factor: 49.962

10.  Morbidity of prophylactic lymph node dissection in the central neck area in patients with papillary thyroid carcinoma.

Authors:  J F Henry; L Gramatica; A Denizot; A Kvachenyuk; M Puccini; T Defechereux
Journal:  Langenbecks Arch Surg       Date:  1998-04       Impact factor: 3.445

View more
  18 in total

Review 1.  Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls.

Authors:  Giuseppe Costante; Cosimo Durante; Zélia Francis; Martin Schlumberger; Sebastiano Filetti
Journal:  Nat Clin Pract Endocrinol Metab       Date:  2009-01

2.  Interest of sentinel node biopsy in apparently intrathyroidal medullary thyroid cancer: a pilot study.

Authors:  M Puccini; G Manca; C Ugolini; V Candalise; A Passaretti; J Bernardini; G Boni; P Buccianti
Journal:  J Endocrinol Invest       Date:  2014-06-21       Impact factor: 4.256

Review 3.  Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma.

Authors:  Samuel A Wells; Sylvia L Asa; Henning Dralle; Rossella Elisei; Douglas B Evans; Robert F Gagel; Nancy Lee; Andreas Machens; Jeffrey F Moley; Furio Pacini; Friedhelm Raue; Karin Frank-Raue; Bruce Robinson; M Sara Rosenthal; Massimo Santoro; Martin Schlumberger; Manisha Shah; Steven G Waguespack
Journal:  Thyroid       Date:  2015-06       Impact factor: 6.568

4.  The RET E616Q Variant is a Gain of Function Mutation Present in a Family with Features of Multiple Endocrine Neoplasia 2A.

Authors:  William Grey; Rosaline Hulse; Anna Yakovleva; Dilyana Genkova; Benjamin Whitelaw; Ellen Solomon; Salvador J Diaz-Cano; Louise Izatt
Journal:  Endocr Pathol       Date:  2017-03       Impact factor: 3.943

Review 5.  New developments in the diagnosis and treatment of thyroid cancer.

Authors:  David F Schneider; Herbert Chen
Journal:  CA Cancer J Clin       Date:  2013-06-24       Impact factor: 508.702

Review 6.  [Hereditary thyroid cancer].

Authors:  H Dralle; A Machens; K Lorenz
Journal:  Chirurg       Date:  2008-11       Impact factor: 0.955

7.  [Surgery of thyroid carcinoma].

Authors:  H Dralle; K Lorenz; A Machens
Journal:  Chirurg       Date:  2009-11       Impact factor: 0.955

8.  A Korean family of familial medullary thyroid cancer with Cys618Ser RET germline mutation.

Authors:  Jinhyang Jung; Shinya Uchino; Youngha Lee; Hoyong Park
Journal:  J Korean Med Sci       Date:  2010-01-21       Impact factor: 2.153

9.  Timing and extent of thyroid surgery for gene carriers of hereditary C cell disease--a consensus statement of the European Society of Endocrine Surgeons (ESES).

Authors:  Bruno Niederle; Frédéric Sebag; Michael Brauckhoff
Journal:  Langenbecks Arch Surg       Date:  2013-12-03       Impact factor: 3.445

10.  Factors predicting outcome of total thyroidectomy in young patients with multiple endocrine neoplasia type 2: a nationwide long-term follow-up study.

Authors:  Jennifer M J Schreinemakers; Menno R Vriens; Gerlof D Valk; Jan-Willem B de Groot; John T Plukker; Klaas M A Bax; Jaap F Hamming; Rob B van der Luijt; Daniel C Aronson; Inne H M Borel Rinkes
Journal:  World J Surg       Date:  2010-04       Impact factor: 3.352

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.